Home › Essential Thrombocythemia › Massachusetts
Essential Thrombocythemia clinical trials in Massachusetts
4 studies for Essential Thrombocythemia are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- University of Massachusetts Medical School, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07623200Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07441694A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002Ruxolitinib in Thrombocythemia and Polycythemia Vera
- Massachusetts General Hospital, Boston
- Beth-Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 8, 2026 · NCT04644211From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.